Ceptur Therapeutics
Dr. Christoph Rosenbohm is the Chief Technology Officer at Ceptur Therapeutics. He was previously Head of Oligonucleotides Technical Development at Roche (2019-2021), Head of Synthesis & Optimization at Roche Innovation Center Copenhagen (2014-2019), and Sr. Director of Research Operation at Santaris Pharma (2010-2014). Dr. Rosenbohm is the author of more than 30 scientific publications and is an inventor on more than 15 patents/applications in the oligonucleotides field
Dr. Rosenbohm holds a Master of Science and a Ph.D. in Organic Chemistry from the University of Southern Denmark (the lab of Prof. Jesper Wengel). After his Ph.D., Christoph worked as a post-doctoral fellow at the Danish Technical Univerisity. In addition, Christoph holds an executive MBA in Technology, Market, and Organisation from Copenhagen Business School.
This person is not in any offices
Ceptur Therapeutics
Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases.